Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis

Chest

Volumn 128, Issue 5, 2005, Pages 3364-3371

  Schiff, Renée L ^a   Kahn, Susan R ^a,b   Shrier, Ian ^b   Strulovitch, Carla ^b   Hammouda, Wahbi ^b   Cohen, Eva ^b   Zukor, David ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Deep venous thrombosis; Low molecular weight heparin; Orthopedic surgery; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN;

ADULT; AGED; ARTHROPLASTY; ARTICLE; CANADA; CELL HETEROGENEITY; CLINICAL TRIAL; FEMALE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORTHOPEDIC SURGERY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

EID: 28144440130     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.5.3364     Document Type: Article

References (24)

1. Geerts WH, Heit JA, Clagett P, et al. Prevention of venous thromboembolism. Chest 2001; 119(suppl):S132-S175
2. Leclerc JR, Gent M, Hirsch J, et al. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1984 patients. Canadian Collaborative Group. Chest 1998; 114(suppl):115S-118S
3. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint operated patients. Acta Orthop Scand 2000; 71:47-50
4. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg 1999; 81-A:932-940
5. Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 132:853-861
6. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107:122-130
7. Robinson KS, Anderson DR, Gross M, et al. Accuracy of screening compression ultrasonography and clinical examination for the diagnosis of deep vein thrombosis after total hip or knee arthroplasty. Can J Surg 1998; 41:368-373
8. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004; 164:17-26
9. White R, Henderson M. Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 2002; 8:365-371
10. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158:1525-1031
11. Reitman R, Emerson R, Higgins L, et al. A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty. J Arthroplasty 2003; 18:161-168
12. Westrich GH, Haas SB, Mosca P, et al. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. J Bone Joint Surg 2000; 828:795-800
13. Brookenthal KR, Freedman KB, Lotke A, et al. A meta-analysis of thromboembolic prophylaxis in total knee arthoplasty. J Arthroplasty 2001; 16:293-300
14. Westrich GH, Menezes A, Sharrock N, et al. Thromboembolic disease prophylaxis in total knee artliroplasty using intraoperative heparin and postoperative pneumatic foot compression. J Arthroplasty 1999; 14:651-656
15. Westrich GH, Farell C, Bono JV, et al. The incidence of venous thromboembolism after total hip arthoplasty: a specific hypotensive epidural anesthesia protocol. J Arthroplasty 1999; 14:456-463
16. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107:19-116
17. Cornelli U, Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Haemost 1999; 259(suppl):57-61
18. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Haemost. 2000; 26(suppl):31-38
19. Planes A, Vochelle N, Fagola M, et al. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagul Fibrinolysis 1998; 9:499-505
20. Planes A, Meyer M, Samama A, et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81:22-25
21. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292:89-96
22. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96:61-68
23. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-anulysis of the randomized trials. Lancet 2001; 358:9-15
24. Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002; 162:1465-1471